Top

Published in:

01-08-2009 | Original

Effects of intravenous and inhaled levosimendan in severe rodent sepsis

Authors: Patrick Scheiermann, Devan Ahluwalia, Sandra Hoegl, Andrea Dolfen, Marc Revermann, Bernhard Zwissler, Heiko Muhl, Kim A. Boost, Christian Hofstetter

Published in: Intensive Care Medicine | Issue 8/2009

Abstract

Purpose

We aimed at comparing the effects of intravenous (i.v.) and inhaled (inh.) levosimendan (LEVO) on survival, inflammatory cytokines and the apoptotic mediator caspase-3 in a rat model of severe sepsis induced by cecal ligation and incision (CLI).

Methods

Twenty-eight anesthetized/ventilated male Sprague–Dawley rats (body weight 528 ± 20 g) underwent laparotomy. Cecal mobilisation served as control (SHAM, n = 7). In all other groups, severe sepsis was induced by CLI. No further intervention occurred in the CLI-group (n = 7). 180 min after CLI, 24 μg/kg i.v. LEVO was administered in the CLI + LEVO-IV-group (n = 7), and 24 μg/kg inh. LEVO was administered via jet nebulizer in the CLI + LEVO-INH-group (n = 7).

Results

CLI induced arterial hypotension, with i.v. and inh. LEVO attenuating blood pressure decrease over 390 min [CLI 34(31/50), CLI + LEVO-IV 82(69/131)*, CLI + LEVO-INH 78(62/85)* mmHg; median(25/75% quartile), *P < 0.05]. CLI induced metabolic acidosis. I.v. and inh. LEVO avoided arterial pH [CLI 7.18(7.16/7.2), CLI + LEVO-IV 7.27(7.24/7.31)*, CLI + LEVO-INH 7.26(7.24/7.28)*] and base excess deterioration [CLI −19(−21.8/−17.9), CLI + LEVO-IV −13(−14.8/−12)*, CLI + LEVO-INH −12.7(−14/−12.2)* mmol/l]. Overall mortality in the CLI-group was 57% compared to 0%* in both LEVO-treated groups after 390 min. LEVO administration significantly attenuated the increase in proinflammatory interleukin (IL)-1β [CLI 896(739/911), CLI + LEVO-IV 302(230/385)*, CLI + LEVO-INH 346(271/548) pg/ml] and IL-6 [CLI 35651(31413/35816), CLI + LEVO-IV 21156(18397/28026), CLI + LEVO-INH 13674(10105/24843) pg/ml] in the plasma and reduced cleaved caspase-3 expression in the spleen.

Conclusions

In a rat model of severe sepsis induced by CLI, i.v. and inh. LEVO equally attenuated arterial hypotension, metabolic acidosis and prolonged survival. Moreover, i.v. and inh. LEVO inhibited proinflammatory mediator release and reduced splenic caspase-3 expression.

Padkin A, Goldfrad C, Brady AR, Young D, Black N, Rowan K (2003) Epidemiology of severe sepsis occurring in the first 24 h in intensive care units in England, Wales, and Northern Ireland. Crit Care Med 31:2332–2338PubMedCrossRef

Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Intensive Care Med 29:530–538PubMed

Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL (2008) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 34:17–60PubMedCrossRef

Kivikko M, Lehtonen L (2005) Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure. Curr Pharm Des 11:435–455PubMedCrossRef

Archan S, Toller W (2008) Levosimendan: current status and future prospects. Curr Opin Anaesthesiol 21:78–84PubMedCrossRef

Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Poder P, Kivikko M (2007) Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA 297:1883–1891PubMedCrossRef

Fries M, Ince C, Rossaint R, Bleilevens C, Bickenbach J, Rex S, Mik EG (2008) Levosimendan but not norepinephrine improves microvascular oxygenation during experimental septic shock. Crit Care Med 36:1886–1891PubMedCrossRef

Behrends M, Peters J (2003) The calcium sensitizer levosimendan attenuates endotoxin-evoked myocardial dysfunction in isolated guinea pig hearts. Intensive Care Med 29:1802–1807PubMedCrossRef

Dubin A, Murias G, Sottile JP, Pozo MO, Baran M, Edul VS, Canales HS, Etcheverry G, Maskin B, Estenssoro E (2007) Effects of levosimendan and dobutamine in experimental acute endotoxemia: a preliminary controlled study. Intensive Care Med 33:485–494PubMedCrossRef

10.

Morelli A, De Castro S, Teboul JL, Singer M, Rocco M, Conti G, De Luca L, Di Angelantonio E, Orecchioni A, Pandian NG, Pietropaoli P (2005) Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med 31:638–644PubMedCrossRef

11.

Strasser A, O’Connor L, Dixit VM (2000) Apoptosis signaling. Annu Rev Biochem 69:217–245PubMedCrossRef

12.

Wesche DE, Lomas-Neira JL, Perl M, Chung CS, Ayala A (2005) Leukocyte apoptosis and its significance in sepsis and shock. J Leukoc Biol 78:325–337PubMedCrossRef

13.

Louhelainen M, Vahtola E, Kaheinen P, Leskinen H, Merasto S, Kyto V, Finckenberg P, Colucci WS, Levijoki J, Pollesello P, Haikala H, Mervaala EM (2007) Effects of levosimendan on cardiac remodeling and cardiomyocyte apoptosis in hypertensive Dahl/Rapp rats. Br J Pharmacol 150:851–861PubMedCrossRef

14.

Boost KA, Hoegl S, Dolfen A, Czerwonka H, Scheiermann P, Zwissler B, Hofstetter C (2008) Inhaled levosimendan reduces mortality and release of proinflammatory mediators in a rat model of experimental ventilator-induced lung injury. Crit Care Med 36:1873–1879PubMedCrossRef

15.

Cunha-Goncalves D, Perez-de-Sa V, Dahm P, Grins E, Thorne J, Blomquist S (2007) Cardiovascular effects of levosimendan in the early stages of endotoxemia. Shock 28:71–77PubMedCrossRef

16.

Scheiermann P, Hoegl S, Revermann M, Ahluwalia D, Zander J, Boost KA, Nguyen T, Zwissler B, Muhl H, Hofstetter C (2009) Cecal ligation and incision: an acute onset model of severe sepsis in rats. J Surg Res 151:132–137PubMedCrossRef

17.

Boost KA, Flondor M, Hofstetter C, Platacis I, Stegewerth K, Hoegl S, Nguyen T, Muhl H, Zwissler B (2007) The beta-adrenoceptor antagonist propranolol counteracts anti-inflammatory effects of isoflurane in rat endotoxemia. Acta Anaesthesiol Scand 51:900–908PubMedCrossRef

18.

Hofstetter C, Boost KA, Flondor M, Basagan-Mogol E, Betz C, Homann M, Muhl H, Pfeilschifter J, Zwissler B (2007) Anti-inflammatory effects of sevoflurane and mild hypothermia in endotoxemic rats. Acta Anaesthesiol Scand 51:893–899PubMedCrossRef

19.

Hofstetter C, Flondor M, Hoegl S, Thein E, Kemming G, Kisch-Wedel H, Kreyling W, Zwissler B (2004) Aerosol delivery during mechanical ventilation to the rat. Exp Lung Res 30:635–651PubMedCrossRef

20.

Hoegl S, Boost KA, Flondor M, Scheiermann P, Muhl H, Pfeilschifter J, Zwissler B, Hofstetter C (2008) Short-term exposure to high-pressure ventilation leads to pulmonary biotrauma and systemic inflammation in the rat. Int J Mol Med 21:513–519PubMed

21.

Rosevear PR, Finley N (2003) Molecular mechanism of levosimendan action: an update. J Mol Cell Cardiol 35:1011–1015PubMedCrossRef

22.

Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N (1997) Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol 333:249–259PubMedCrossRef

23.

Szilagyi S, Pollesello P, Levijoki J, Haikala H, Bak I, Tosaki A, Borbely A, Edes I, Papp Z (2005) Two inotropes with different mechanisms of action: contractile, PDE-inhibitory and direct myofibrillar effects of levosimendan and enoximone. J Cardiovasc Pharmacol 46:369–376PubMedCrossRef

24.

Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, Nyquist O, Remme WJ (2000) Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 36:1903–1912PubMedCrossRef

25.

Antila S, Kivikko M, Lehtonen L, Eha J, Heikkila A, Pohjanjousi P, Pentikainen PJ (2004) Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan. Br J Clin Pharmacol 57:412–415PubMedCrossRef

26.

Singh S, Evans TW (2006) Organ dysfunction during sepsis. Intensive Care Med 32:349–360PubMedCrossRef

27.

Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345:1368–1377PubMedCrossRef

28.

Varpula M, Tallgren M, Saukkonen K, Voipio-Pulkki LM, Pettila V (2005) Hemodynamic variables related to outcome in septic shock. Intensive Care Med 31:1066–1071PubMedCrossRef

29.

Zager RA, Johnson AC, Lund S, Hanson SY, Abrass CK (2006) Levosimendan protects against experimental endotoxemic acute renal failure. Am J Physiol Renal Physiol 290:F1453–F1462PubMedCrossRef

30.

Hotchkiss RS, Swanson PE, Cobb JP, Jacobson A, Buchman TG, Karl IE (1997) Apoptosis in lymphoid and parenchymal cells during sepsis: findings in normal and T- and B-cell-deficient mice. Crit Care Med 25:1298–1307PubMedCrossRef

31.

Hotchkiss RS, Coopersmith CM, Karl IE (2005) Prevention of lymphocyte apoptosis––a potential treatment of sepsis? Clin Infect Dis 41(Suppl 7):S465–S469PubMedCrossRef

32.

Hotchkiss RS, Chang KC, Swanson PE, Tinsley KW, Hui JJ, Klender P, Xanthoudakis S, Roy S, Black C, Grimm E, Aspiotis R, Han Y, Nicholson DW, Karl IE (2000) Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat Immunol 1:496–501PubMedCrossRef

33.

Oberbeck R, Schmitz D, Wilsenack K, Schuler M, Pehle B, Schedlowski M, Exton MS (2004) Adrenergic modulation of survival and cellular immune functions during polymicrobial sepsis. Neuroimmunomodulation 11:214–223PubMedCrossRef

34.

Oberbeck R, Schmitz D, Wilsenack K, Schuler M, Husain B, Schedlowski M, Exton MS (2006) Dopamine affects cellular immune functions during polymicrobial sepsis. Intensive Care Med 32:731–739PubMedCrossRef

35.

Oberbeck R, Schmitz D, Schuler M, Wilsenack K, Schedlowski M, Exton M (2004) Dopexamine and cellular immune functions during systemic inflammation. Immunobiology 208:429–438PubMedCrossRef

Title: Effects of intravenous and inhaled levosimendan in severe rodent sepsis
Authors: Patrick Scheiermann
Devan Ahluwalia
Sandra Hoegl
Andrea Dolfen
Marc Revermann
Bernhard Zwissler
Heiko Muhl
Kim A. Boost
Christian Hofstetter
Publication date: 01-08-2009
Publisher: Springer-Verlag
Published in: Intensive Care Medicine / Issue 8/2009
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-009-1481-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Effects of intravenous and inhaled levosimendan in severe rodent sepsis

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2009

CONTRA: Hydroxyethyl starch solutions are unsafe in critically ill patients

Danaparoid cross-reactivity with heparin-induced thrombocytopenia antibodies: report of 12 cases

Teaching improves adherence to clinical guidelines in the treatment of oral anticoagulation-related severe bleeding in the emergency department

Effect of tidal volume in children with acute hypoxemic respiratory failure

Blood acidification enhances carbon dioxide removal of membrane lung: an experimental study

Response to the letter of Shyamsundar et al.